Surface-modified mesoporous silica nanoparticles for blood-brain barrier penetration, tumor targeting and cancer metastasis treatment, their preparation method and use

Surface-modified mesoporous silica nanoparticles address the challenges of tumor targeting and BBB penetration, achieving effective drug delivery and metastasis inhibition for brain and CNS diseases.

JP7586456B2Active Publication Date: 2024-11-19NANO TARGETING & THERAPY BIOPHARMA INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020080729
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-03
Filing Date
2020-04-30
Publication Date
2024-11-19
Estimated Expiration
2040-04-30

AI Technical Summary

Technical Problem

Existing drug delivery systems face challenges in targeting tumors effectively due to the enhanced vascular permeability and retention (EPR) effect, and they are hindered by the blood-brain barrier (BBB) when treating central nervous system (CNS) diseases and cancer metastasis remains a significant threat to patient survival.

Method used

Surface-modified mesoporous silica nanoparticles (MSNs) with specific size, charge, and functional groups, such as PEGylation and positively charged moieties, are developed to enhance tumor targeting and BBB penetration, allowing for controlled drug delivery and inhibition of cancer metastasis.

Benefits of technology

The modified MSNs exhibit enhanced accumulation in tumors, cross the BBB, and inhibit cancer metastasis, providing effective treatment for brain-related cancers and CNS diseases, with improved pharmacokinetics and biodistribution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586456000005
    Figure 0007586456000005
  • Figure 0007586456000006
    Figure 0007586456000006
  • Figure 0007586456000007
    Figure 0007586456000007
Patent Text Reader

Abstract

To provide: mesoporous silica nanoparticles (MSNs) with specific modifications containing both tumor-targeting and blood-brain barrier (BBB) penetration properties suitable for cancer treatment and / or CNS disease treatment; a method of preparing MSNs; and MSNs prepared by the method.SOLUTION: A mesoporous silica nanoparticle having an organic modification with a poly(ethylene glycol) (PEG) moiety and at least one positively charged group-containing oligomer / polymer has a zeta potential in the range from -22 mV to +25 mV at pH 7.4, and a particle size of 50 nm or less.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to mesoporous silica nanoparticles as drug delivery systems for carrying bioactive ingredients for treating cancer or as active agents for inhibiting cancer metastasis. [Background technology]

[0002] Mesoporous silica nanoparticles (MSNs) have been considered to have great potential as drug delivery systems due to their unique physical and chemical properties, such as large pore volume, chemical and thermal stability, high loading capacity, tunable surface properties, and excellent biocompatibility. MSNs have been widely used in the treatment of diseases in the past decade because of their ability to deliver various types of therapeutic agents to target sites. Among diseases, cancer is the second leading cause of death worldwide, with approximately 9.6 million deaths from cancer in 2018. Nanoparticles have served the purpose of curing multiple types of cancer, and special therapeutic effects based on the tumor targeting and controlled / sustained drug release properties of nanoparticles have also been demonstrated. Passive tumor targeting of nanoparticles is due to the accumulation of nanoparticles in tumors due to the enhanced vascular permeability and retention (EPR) effect of solid tumors, leaky vasculature, and lack of effective lymphatic drainage in solid tumors.

[0003] Another challenge is treating diseases of the central nervous system (CNS), such as Alzheimer's disease (AD), Parkinson's disease (PD), and brain tumors, which are areas of high unmet medical need due to the blood-brain barrier (BBB) ​​restricting the transport of most therapeutic drugs to the brain. Essentially, 100% of macromolecular drugs and more than 95% of small molecule drugs cannot enter the brain. Versatile nanoparticle drug delivery systems are considered as a potential way to overcome the BBB restriction for the treatment of central nervous system (CNS) diseases.

[0004] Furthermore, when a cancer patient's cancer metastasis occurs, the chances of the patient dying increase dramatically, so it is important to improve the prognosis of cancer patients, especially metastatic cancer, by preventing, inhibiting, or suppressing the occurrence of cancer metastasis.

[0005] Thus, there is a need for improved mesoporous silica nanoparticles as drug delivery systems or active ingredients, and reliable methods for synthesizing such mesoporous silica nanoparticles. Summary of the Invention

[0006] The present disclosure relates to mesoporous silica nanoparticles (MSNs) with special modifications as drug delivery systems with both tumor targeting and blood-brain barrier (BBB) ​​permeation properties suitable for the treatment of cancer and / or CNS diseases.

[0007] The present disclosure also relates to mesoporous silica nanoparticles (MSNs) with special modifications as therapeutic agents for preventing, inhibiting or suppressing cancer metastasis.

[0008] The present disclosure also provides products prepared by the above methods. [Brief description of the drawings]

[0009] [Figure 1A] A TEM image of 30 nm MSN-PEG is shown. [Figure 1B] TEM image of MSN-PEG+TA (2:1) is shown. [Diagram 2] The ratio of particles accumulated in the tumor relative to the liver (tumor / liver) for 30 nm MSN-PEG is shown. [Diagram 3] The ratio of particles accumulated in the tumor relative to the liver (tumor / liver) is shown for 30 nm MSN-PEG+TA nanoparticles. [Figure 4A] 1 shows three-dimensional images of 30 nm MSN-PEG+TA in cerebral blood vessels detected by two-photon fluorescence microscopy. [Figure 4B]1 shows three-dimensional images of 30 nm MSN-PEG+THPMPs in cerebral blood vessels detected by two-photon fluorescence microscopy. [Figure 5A] 1 shows the results of an in vitro test to evaluate the effect of inhibiting cell migration. [Figure 5B] 1 shows the results of an in vitro test to evaluate the effect of inhibiting cell migration. [Figure 6A] 1 shows the results of an in vivo study to evaluate the toxicity of MSNs to mice. [Figure 6B] 1 shows the results of an in vivo study to evaluate the toxicity of MSNs to mice. [Figure 7] 1 shows the results of an in vivo study to evaluate the effect of inhibiting metastasis of breast cancer to the lungs. [Figure 8] The results of the luminescence assay to evaluate the effect of inhibiting cancer metastasis are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] To facilitate understanding of this disclosure, the following definitions are provided for certain terms used herein.

[0011] In the specification and claims, the singular forms include the plural forms unless otherwise indicated, and unless otherwise indicated, all examples or illustrative words (e.g., "such as") used herein are not intended to limit the scope of the invention but are merely used to more clearly illustrate the invention.

[0012] It is to be understood that any numerical range described herein is intended to include all subranges. For example, the range "50-70°C" includes all subranges and specific values ​​between the minimum value of 50°C and the maximum value of 70°C, such as 58°C-67°C, 53°C-62°C, 60°C, or 68°C. The numerical ranges of the present disclosure are continuous and therefore include each value between the minimum and maximum values. Unless otherwise specified, the various numerical ranges set forth herein are approximate ranges.

[0013] According to the present invention, the term "about" refers to an acceptable deviation of a given value measured by a person of ordinary skill in the art, depending on how the value is measured or determined.

[0014] In accordance with the present invention, unless otherwise specified, the prefix "nano" as used herein means a size of about 300 nm or less. Unless otherwise specified, the prefix "meso" as used herein means a size of about 5 nm or less, as defined by the International Union of Pure and Applied Chemistry (IUPAC).

[0015] According to the present invention, the term "silane" as used herein refers to a derivative of SiH4. Typically, at least one of the four hydrogens is replaced with a substituent such as alkyl, alkoxyl, amino, etc., as described below. The term "alkoxysilane" as used herein refers to a silane having at least one alkoxyl substituent bonded directly to the silicon atom. The term "organoalkoxysilane" as used herein refers to a silane having at least one alkoxyl substituent bonded directly to the silicon atom and at least one hydrocarbyl substituent. The term "silicate source" as used herein refers to a material that can be considered as a salt or ester form of orthosilicic acid, such as, for example, sodium orthosilicate, sodium metasilicate, tetraethylorthosilicate (tetraethoxysilane, TEOS), tetramethylorthosilicate, tetrapropylorthosilicate, etc. Optionally, the hydrocarbyl substituent may be further substituted or interrupted by a heteroatom.

[0016] According to the present invention, the term "hydrocarbyl" as used herein refers to a monovalent group derived from a hydrocarbon. As used herein, the term "hydrocarbon" refers to a molecule consisting of only carbon and hydrogen atoms. Examples of hydrocarbons include, but are not limited to, (cyclo)alkanes, (cyclo)alkenes, alkadienes, aromatics, and the like. When the hydrocarbyl is further substituted as described above, the substituents may be halogens, amino groups, hydroxy groups, thiol groups, and the like. When the hydrocarbyl is interrupted by a heteroatom as described above, the heteroatom may be S, O, or N. According to the present invention, the hydrocarbyl preferably consists of 1 to 30 carbon atoms.

[0017] According to the present invention, the term "alkyl" as used herein refers to saturated, straight or branched chain alkyl, preferably consisting of 1 to 30 carbon atoms, more preferably 1 to 20 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2-ethylbutyl, n-pentyl, isopentyl, 1-methylpentyl, 1,3-dimethylbutyl, n-hexyl, 1-methylhexyl, n-heptyl, isoheptyl, 1,1,3,3-tetramethylbutyl, 1-methylheptyl, 3-methylheptyl, n-octyl, 2-ethylhexyl, 1,1,3-trimethylhexyl, 1,1,3,3-tetramethylpentyl, nonyl, decyl, undecyl, 1-methylundecyl, dodecyl, 1,1,3,3,5,5-hexamethylhexyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like.

[0018] According to the present invention, the term "alkylene" refers to a divalent group of alkyl as defined above. The term "short chain" denotes that the radical or repeating unit contains at most 6, preferably at most 4, carbon atoms in the main chain.

[0019] According to the present invention, the term "alkoxyl" or "alkoxy" as used herein refers to a group having the formula "-O-alkyl", in which the definition of "alkyl" has the meaning of "alkyl" as defined above.

[0020] In accordance with the present invention, the term "cycloalkyl" as used herein refers to a saturated or partially unsaturated cyclic carbocyclic radical having 3 to 10 ring carbon atoms, more preferably 3 to 8 ring carbon atoms, and optionally containing alkyl substituents on the ring. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclopropenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-cyclohexen-1-yl, and the like.

[0021] According to the present invention, the term "halogen" or "halo" as used herein denotes fluorine, chlorine, bromine or iodine.

[0022] According to the present invention, the term "amino" as used herein refers to a functional group of formula -NR1R2, where R1 and R2 each represent a halogen or a hydrocarbyl group as defined above.

[0023] According to the present invention, the term "aqueous phase" as used herein means a phase that is substantially miscible with water. Examples of aqueous phases include, but are not limited to, water itself, aqueous buffers, aqueous dimethylsulfoxide (DMSO), aqueous alkanolic solutions, etc. The aqueous phase may be adjusted to be acidic, neutral, or alkaline based on the needs of the synthesis and / or the stability of the substances present in the aqueous phase.

[0024] According to the present invention, the term "oil phase" as used herein means a phase that is substantially immiscible with the aqueous phase as described above. Examples of oil phases include, but are not limited to, liquid substituted or unsubstituted (cyclo)alkanes such as hexane, decane, octane, dodecane, cyclohexane, and substituted or unsubstituted aromatic solvents such as benzene, toluene, xylene, and the like.

[0025] According to the present invention, the term "bioactive ingredient" as used herein refers to a substance that has activity in a living organism. Examples of bioactive ingredients include, but are not limited to, small molecule drugs, proteins such as enzymes and protein drugs, antibodies, vaccines, antibiotics, or nucleotide drugs.

[0026] According to the present invention, the term "solid silica nanoparticles" as used herein refers to silica nanoparticles having a non-porous surface, in particular a non-mesopore structure.

[0027] The present invention has made a surprising discovery that the in vitro and in vivo actions of MSNs can be controlled by the surface modification and physicochemical properties of MSNs, including size, shape, surface charge, and spatial distribution of functional groups, as determinants of MSNs' tumor targeting ability (e.g., EPR effect) and BBB permeability. The outer surface of MSNs is modified with short-chain poly(alkylene glycol)s (PAGs), such as poly(ethylene glycol)s (PEGs), poly(propylene glycols) (PPGs), and PEG-PPG copolymers, and charged molecules hidden within the PAG layer are introduced at a specific PAG / charged molecule molar ratio. Their modification, spatial arrangement, and charge reveal the characteristics of MSNs, including minimal nonspecific binding and adequate circulation time in physiological environments, allowing MSNs to be transported from blood to the brain.

[0028] For example, modification with poly(alkylene glycol) (PAG), such as poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG), can prevent MSNs from being absorbed by serum proteins and inhibit clearance by the reticuloendothelial system. Further modifiers can be introduced to modify the properties (e.g., surface properties) of MSNs. It has been observed that when PEG is used as a surface modifier and the modifier is exposed on the outer surface rather than hidden deep within the PEG layer, MSNs nonspecifically bind to proteins or cells in a physiological environment, resulting in rapid in vivo clearance and no accumulation in tumors.

[0029] Therefore, the present disclosure uses charge-modulating molecules, especially modifiers with positively charged groups and shorter length on the surface of MSNs than PEG. To evaluate the effect of surface charge on the EPR effect of PEGylated MSNs (MSN-PEG), the present disclosure synthesizes size, shape, hydrodynamic diameter, and spatial distribution-compatible MSNs with various surface charges by modulating the ratio of PEG to charged molecules present in MSN-PEG. A study of the biodistribution of MSNs in tumor-bearing mice found that one of the factors affecting the efficacy of administration and recirculation of MSNs is the zeta potential. For example, the zeta potential of modified MSNs (at pH 7.4) can be in the range of -22 to +25 mV, preferably -22 to +21 mV, -21 to +25 mV, etc. In one embodiment, 30 nm of MSN-PEG+TA (MSN modified with PEG and N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA)) has a zeta potential in the range of -22 to +21 mV, preferably -15 to +17 mV, more preferably about -13 to +7 mV, or in other examples, up to +4 mV, and exhibits excellent EPR effect (e.g., the ratio of tumor signal to liver signal (tumor / liver) is greater than 1, and the tumor / liver value is greater than the tumor / liver value of MSN-PEG). In one embodiment, 50 nm of MSN-PEG+TA has a zeta potential in the range of -21 to +25 mV, preferably -21 to +18 mV (pH 7.4 state), and exhibits excellent EPR effect.

[0030] Another factor that influences the tumor targeting ability (EPR effect) of surface-modified MSNs is the molar ratio of PEG groups to positively charged groups in MSNs. The molar ratio of PEG / positively charged groups is determined by elemental analysis. The PEG / positively charged group ratio can fall within a certain range. In one example, the ratio is in the range of 0.5-15, preferably about 2-10, more preferably 2-6.5. It is observed and expected that MSNs with such a specific PEG / charged group ratio can exhibit excellent EPR effect.

[0031] Other factors that influence the effectiveness of MSNs to act as drug delivery systems include, but are not limited to, particle size, type of (surface) modifier, particle morphology, etc.

[0032] The present invention also made the surprising discovery that surface-modified MSNs can cross the blood-brain barrier (BBB). The BBB is a crucial physiological barrier in the central nervous system that controls the transfer of ions and molecules from the circulating blood into the brain and prevents pathogens and toxic agents from entering the brain. However, the BBB has a problem in treating brain diseases, where most drugs are hindered by the BBB. Conventional methods to overcome the BBB problem are limited to smaller, more versatile nanoparticles, and consider functionalizing the surface to cross the BBB. However, the effect of these various characterizations of nanoparticles on controlling BBB penetration has yet to be elucidated. To develop unique silica nanoparticles with BBB penetration ability for drug delivery to CNS diseases, the present disclosure rationally designed and synthesized MSNs with different sizes, charges, and functional ligands.

[0033] Thus, the present disclosure demonstrates MSN-PEG+TA with a specific range of surface charge that has the ability to cross the BBB. In one embodiment, 30 nm MSN-PEG+TA with a zeta potential in the range of -15 to +21 mV, preferably -13 to +17 mV, more preferably about -13 to +7 mV (6.4 mV in one example) at pH 7.4 has the ability to cross the BBB. As described above, the surface charge of MSN can be modulated by attaching different ratios of PEG / charged molecules to MSN, and the charged molecules must be present in the PEG layer. The PEG / positively charged group molar ratio, which is the molar ratio of PEG groups to positively charged groups in MSN, is determined by elemental analysis. The PEG / positively charged group ratio can fall within a specific range. In one example, the ratio is 0.5 to 15, preferably about 2 to 10, more preferably 2 to 6.5 (6.13 in one example). It is observed and expected that MSNs with such a PEG / charged group ratio may exhibit superior BBB permeability.

[0034] MSNs with both EPR effect and BBB penetration ability would show advantages to be promising drug delivery systems for the treatment of brain-related cancers and CNS diseases. All examples, materials, reaction conditions, or parameters shown are not intended to limit the materials or preparation methods according to the exemplary embodiments described herein.

[0035] Surface-modified mesoporous silica nanoparticles (MSNs) and their preparation methods

[0036] In one aspect, the present disclosure provides mesoporous silica nanoparticles whose surface is organically modified, have a zeta potential in the range of -22 mV to +25 mV at pH 7.4, and have a particle size of 50 nm or less. The organic modification includes a poly(ethylene glycol) moiety and at least one positively charged group-containing oligomer / polymer moiety. The molar ratio of the poly(ethylene glycol) moiety to the positively charged group-containing oligomer / polymer moiety can fall within a specific range, for example, 0.5 to 15, which can be determined by elemental analysis.

[0037] In one embodiment, the mesoporous silica nanoparticles of the present disclosure have a particle size of 30 nm or less.

[0038] In one embodiment, the mesoporous silica nanoparticles of the present disclosure have a zeta potential ranging from -15 mV to +4 mV at pH 7.4, and in another preferred embodiment, a zeta potential ranging from -13 mV to +7 mV at pH 7.4.

[0039] In one embodiment, the mesoporous silica nanoparticles of the present disclosure have a specific ratio of poly(ethylene glycol) moieties to positively charged group-containing oligomer / polymer moieties ranging from 2 to 6.5.

[0040] In one embodiment, the surface modification of MSNs comprises an organic modification comprising at least one moiety that enhances bioavailability and at least one moiety that modulates the properties of the surface charge. In one embodiment, the moiety that enhances bioavailability is derived from or introduced by a surface modifier. In one embodiment, the moiety that modulates the properties of the surface charge is derived from a charge-modulating molecule, in particular a positively charged group-containing oligomer / polymer. In one embodiment, the positively charged group-containing oligomer / polymer can be a nitrogen-containing oligomer / polymer.

[0041] In one embodiment, the organic modification is a poly(alkylene glycol) (PAG) such as poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), PEG-PPG copolymers; polyethyleneimine (PEI); N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]ethylenediamine (EDPT), N 1 -Alkoxysilane-terminated (poly)alkylene(poly)amines such as (3-trimethoxysilylpropyl)diethylenetriamine; 3-aminopropyltrimethoxysilane (APTMS), propyltriethoxysilane, butyltrimethoxysilane, octyltrimethoxysilane, diphenyldiethoxysilane, n-octyltriethoxysilane, mercaptopropyltrimethoxysilane, chloromethyltrimethoxysilane, isobutyltriethoxysilane, 3-aminopropyltriethoxysilane, ethyltrimethoxystyrenesilane, methyltrimethoxysilane, ethyl ... The silane may be derived from or selected from organoalkoxysilanes such as ethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (EDTAS), (3-trihydroxysilyl)propylmethylphosphonic acid (THPMP), methyltriacetoxysilane (MTAS), (3-mercatopropyl)trimethoxysilane (MPTMS), zwitterionic silanes, and the like.

[0042] In one embodiment, the bioactive component is disposed on the nanoparticle. In another embodiment, the bioactive component is loaded within the nanoparticle. In yet another embodiment, the bioactive component is both disposed on and loaded on the nanoparticle.

[0043] Mesoporous silica nanoparticles (MSNs) have well-defined structures and a high density of surface silanol groups that can be modified by various organic functional groups. MSNs of different sizes are prepared with ammonia as a base catalyst. The particle size is controlled by adjusting the concentration of ammonia, the amount and concentration of silane source, reaction temperature, etc.

[0044] In one aspect, MSNs can be prepared by the steps of: (a) providing an alkaline solution containing a surfactant at a sufficient concentration to form micelles, (b) introducing a silane source to the solution, (c) introducing a surface modifier comprising at least one PEG-modified silane and at least one positively charged group-containing silane to the solution, (d) subjecting the solution to a hydrothermal treatment, (e) collecting the product, (f) removing residual surfactant from the product, and, optionally, (g) purifying or washing the product.

[0045] As an example, 0.29 g of cetyltrimethylammonium bromide (CTAB) was dissolved in 150 mL of ammonium hydroxide solution (0.1-0.2 M) at the desired temperature (50-60 °C) in a sealed beaker. After stirring for 15 min, the sealing membrane was removed and the solution was stirred vigorously (600 rpm) while 2.5 mL of RITC (rhodamine isothiocyanate)-conjugated APTMS in ethanol and 2-2.5 mL of TEOS (0.8-0.9 M) in ethanol were added. After 1 h of stirring, 550 μL of PEG silane (2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane) with different molar ratios of PEG silane to TA silane (N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride) was reacted in 2 mL of ethanol (PEG / TA ratios were 15:1, 10:1, 7:1, 3:1, 2:1, and 1:2, and the amount of TA silane ranged from 0.04 to 1.2 mL). The mixture was stirred for 30 min, and then the mixture was aged at the desired temperature (50–60 °C) without stirring for at least 12 h. The solution was then sealed and subjected to hydrothermal treatment by placing in a 70 °C oven for 24 h. The as-synthesized samples were washed and collected by centrifugation or a cross-flow system. To remove the surfactant in the pores of MSNs, the as-synthesized samples were incubated in 40 mL of acidic ethanol containing 678 μL and 40 μL of hydrochloric acid (37%) for the first and second times, respectively, at 60 °C and extraction time of 1 h. The products were washed, collected by centrifugation or a cross-flow system, and finally stored in 90% ethanol. To synthesize MSN-PEGs modified with different functional groups, TA silane was replaced with PEI silane, EDPTMSN silane, or other functional silanes.

[0046] In one embodiment, the silane source comprises tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), sodium silicate, or a mixture thereof. In one embodiment, the surface modifier comprises 2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane (PEG-trimethoxysilane), 3-aminopropyltrimethoxysilane (APTMS), propyltriethoxysilane, butyltrimethoxysilane, octyltrimethoxysilane, diphenyldiethoxysilane, n-octyltriethoxysilane, mercaptopropyltrimethoxysilane, chloromethyltrimethoxysilane, isobutyltriethoxysilane, 3-aminopropyltriethoxysilane, ethyltrimethoxystyrenesilane, methyltriethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane, phenyltrimethoxysilane, phenyltrimethoxysilane, phenyltriethoxy ... The silane may be silane (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (EDTAS), (3-trihydroxysilyl)propylmethylphosphonic acid (THPMP), methyltriacetoxysilane (MTAS), N-[3-(trimethoxysilyl)propyl]ethylenediamine, trimethoxysilylpropyl (polyethyleneimine), N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride, (3-mercatopropyl)trimethoxysilane (MPTMS), zwitterionic silane, or mixtures thereof.

[0047] Examples of surfactants suitable for preparing MSN include, but are not limited to, cationic surfactants, anionic surfactants, and nonionic surfactants. Suitable surfactants are selected based on reaction conditions such as pH value, ionic strength, temperature, reactants, and products. Examples of cationic surfactants include, but are not limited to, pH-dependent primary, secondary, or tertiary amines, such as octenidine dihydrochloride, which have long-chain hydrocarbyl groups and terminal amine groups that have a positive charge below a certain pH value (e.g., primary and secondary amines are positively charged at pH<10), and permanently charged quaternary ammonium salts, such as cetyltrimethylammonium bromide (CTAB), cetylpyridinium chloride (CPC), benzalkonium chloride (BAC), benzethonium chloride (BZT), dimethyldioctadecylammonium chloride, and dimethyldioctadecylammonium bromide (DODAB). Examples of anionic surfactants include, but are not limited to, sulfates, sulfonates, and phosphates or esters such as ammonium lauryl sulfate, sodium lauryl sulfate (sodium dodecyl sulfate, SLS or SDS), related alkyl ether sulfates sodium laureth sulfate (sodium laureth sulfate or SLES), sodium myreth sulfate, docusate (dioctyl sodium sulfosuccinate), perfluorooctane sulfonate (PFOS), perfluorobutane sulfonates, alkyl aryl ether phosphates, alkyl ether phosphates, and the like. Examples of nonionic surfactants include, but are not limited to, poly(oxyethylene) nonylphenyl ether, polyoxyethylene glycol sorbitan alkyl esters, polyethylene glycol alkyl ethers, glucoside alkyl ethers, polyethylene glycol octylphenyl ether, polyethylene glycol alkylphenyl ethers, glycerol alkyl esters, polypropylene glycol alkyl ethers, block copolymers, poloxamers, cocamide monoethanolamine (cocamide MEA), cocamide diethanolamine (cocamide DEA), lauryl dimethylamine oxide, or polyethoxylated tallow amine.

[0048] MSN size

[0049] MSNs of different sizes can be prepared using ammonia as a base catalyst. In one aspect, MSNs are prepared in a highly diluted state, i.e., in a state where the concentration of surfactant is low. In the present disclosure, MSNs have a diameter in the range of 20-200 nm, preferably 20-80 nm, more preferably 20-50 nm, and even more preferably 30-40 nm. The size of MSNs can be controlled by adjusting the ammonium concentration, the amount and concentration of alkoxylsilane, reaction temperature, etc. Without being bound by theory, the higher the ammonia concentration, the larger the size of MSNs, and the lower the ammonia concentration, the smaller the size of MSNs. The higher the amount of alkoxylsilane, the larger the size of MSNs, and the lower the amount of alkoxylsilane, the smaller the size of MSNs. In various embodiments, the ammonium concentration of 150 mL of ammonium hydroxide solution in which 0.14-0.5 g of CTAB is dissolved is 0.05-1.5 M, preferably 0.1-0.5 M, more preferably 0.1-0.256 M, and the amount of alkoxylsilane added to the 150 mL of ammonium hydroxide solution is in the range of 1 mL-5 mL, preferably 1 mL-3 mL, more preferably 2 mL-2.5 mL of TEOS (about 0.862 M) in ethanol as a solvent. The reaction temperature is in the range of 30° C.-60° C., preferably 40° C.-60° C., more preferably 50° C.-60° C., and any combination of these conditions constitutes an embodiment of the present disclosure.

[0050] Surface modification of MSNs

[0051] MSNs have a well-defined structure and a high density of surface silanol groups that can be modified by a variety of organic functional groups. Examples of functional groups include, but are not limited to, poly(alkylene glycols) (PAGs) such as poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), and PEG-PPG copolymers; polyethyleneimine (PEI); N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]ethylenediamine (EDPT), N-[3-(trimethoxysilyl)propyl]ethylenediamine (EDPT), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (EDPT ...1 -Alkoxysilane-terminated (poly)alkylene(poly)amines such as (3-trimethoxysilylpropyl)diethylenetriamine; 3-aminopropyltrimethoxysilane (APTMS), propyltriethoxysilane, butyltrimethoxysilane, octyltrimethoxysilane, diphenyldiethoxysilane, n-octyltriethoxysilane, mercaptopropyltrimethoxysilane, chloromethyltrimethoxysilane, isobutyltriethoxysilane, 3-aminopropyltriethoxysilane, ethyltrimethoxystyrenesilane, methyltrimethoxy ... Organoalkoxysilanes such as ethyltriethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (EDTAS), (3-trihydroxysilyl)propylmethylphosphonate (THPMP), methyltriacetoxysilane (MTAS), (3-mercatopropyl)trimethoxysilane (MPTMS), and zwitterionic silanes.

[0052] Nanoparticle parameters of particular importance for biological applications are particle size and surface properties, which are expected to play a key role in the circulation half-life, pharmacokinetics, and biodistribution of nanoparticles in vivo. The size of MSNs affects the pharmacokinetics and biodistribution in the body. Ultrasmall MSNs (e.g., diameter less than 8 nm) are usually quickly removed by renal filtration, while larger nanoparticles (e.g., greater than 150 nm) reside in the liver or spleen. For example, nanoparticles with diameters in the range of 20-100 nm exhibit longer blood half-lives, which promote the tendency of nanoparticles to extravasate by fenestration in the tumor vasculature. In addition, nanoparticles with small size (e.g., less than 50 nm) and long blood half-life may have a higher ability to cross the BBB. The surface of MSNs modified with functional groups will also change the properties of MSNs and their biological application capabilities. For example, functional group modification with poly(alkylene glycol) (PAG) may allow the particles to suspend well in culture media, have low immunogenicity, and have a long circulation period in the body. The surface of MSNs without surface modification usually has a negative charge, but by modification with PEI, alkoxylsilane-terminated (poly)alkylene (poly)amine, or amine-containing organoalkoxysilane, the particles can have a positive or weakly negative surface charge, or be electrically neutral on the surface. By modification with carboxyl, phosphoryl, or sulfonic acid-containing organoalkoxysilane, the particles can have a strong negative charge. Also, the combination of functional groups on the particle surface will result in multiple surface properties. Therefore, the size and surface properties of the particles can be designed or optimized based on the purpose of the biological application.

[0053] Bioactive ingredients

[0054] For the treatment of a disease, at least one bioactive ingredient may be placed and / or loaded onto the MSNs, for example, distributed within the spaces within the MSNs or on the surface of the MSNs. The bioactive ingredient may be appropriately selected based on the size of the MSNs and the disorder / disease in question. Examples of bioactive moieties include, but are not limited to, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-I0l, pazopanib, GSK690693, RTA744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, FLT-3 inhibitors, VEGFR inhibitors, EGFR-TK inhibitors, Aurora kinase inhibitors, PIK-1 modulators, Bcl-2 inhibitors, HDAC inhibitors, c-MET inhibitors, PARP inhibitors, Cdk inhibitors, EGFR TK inhibitors, IGFR-TK inhibitors, anti-HGF antibodies, PI3 kinase inhibitors, AKT inhibitors, JAK / STAT inhibitors, checkpoint 1 or 2 inhibitors, focal adhesion kinase inhibitors, Map kinase kinase (mek) inhibitors, VEGF trap antibodies, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gymatecan, IL13-PE38QQR, INO 1001, IPdR1 KRX-0402, lucanton, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709,Seliciclib; PD0325901, AZD-6244, capecitabine, L-glutamic acid N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrozole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogens, bevacizumab, IMC- 1C11, CHIR-258, 3-[5-(methylsulfonylpiperazinemethyl)-indolyl]-quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, Erbitux, EKB-569, PKI-166, GW-572016, Ionafarnib, BMS-214662, Tipifarnib; Amifostine, NVP-LAQ824, Suberoylanilide hydroxamic acid, Valproic acid, Trichostatin A, FK-228, SU11248, Sorafenib, KRN951, Aminoglutethimide, Amsacrine, Anagrelide, L-Asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, Bleomycin, Buserelin, Busulfan, Carboplatin, Ca Lumustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide,Octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deoxyuridine, cytosine arabinoside, 6-mercaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, Lazoxine, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimetidine, trastuzumab, denileukin diftitox, gefitinib, bortezomib, paclitaxel, cremophor-free paclitaxel, docetaxel, epothilone B B), BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787 / ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zoledronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin,Pegylated interferon alpha-2a, interferon alpha-2a, pegylated interferon alpha-2b, interferon alpha-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans retinoic acid, ketoconazole, interleukin-2, megestrol, immunoglobulin, nitrogen mustard, methylprednisolone, ibritumomab tiuxetan tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, etidronate, mitotane, cyclosporine, liposomal daunorubicin, edwina-asparaginase, strontium-89, casopitant, netupitant, NK-1 receptor antagonists , palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, and darbepoetin alfa.

[0055] EPR effect

[0056] In general, passive targeting by the EPR effect is highly dependent on the long circulation time of nanocarriers. Approaches to tumor targeting based on the high permeability and retention (EPR) effect would be (1) high density PEGylation, (2) spatial control of functional groups on the surface, (3) generation of small mesoporous silica nanoparticles (MSNs), and (4) control of protein corona formation. Two particularly important parameters are particle size and surface properties, which are expected to play key roles in the circulation half-life, pharmacokinetics, and biodistribution of nanoparticles. In general, injected substances are recognized and quickly bound by serum opsonins, and then phagocytosed and substantially accumulated in both the liver and spleen (also known as the mononuclear phagocyte system). Furthermore, comprehensive studies have highlighted the neutrality of the protein corona as a key design in the development of targeted nanomaterial delivery, proving that even small differences in surface heterogeneity can lead to significantly different interactions with cells and tissues. Therefore, controlling and understanding the protein corona composition will be important for the successful development of nanomedicines by the EPR effect.

[0057] BBB penetration effect

[0058] The blood-brain barrier (BBB) ​​restricts most therapeutic agents from being transported into the brain. Nanomedicine can modulate the size, shape, surface charge, and conjugated ligands of nanoparticles to improve BBB penetration. For example, nanoparticles conjugated to targeting ligands that bind to receptors in endothelial cells, such as transferrin, lactoferrin, glutathione, and low-density lipoprotein receptors, can also promote BBB penetration. However, modification of the outer surface of nanoparticles with targeting ligands can also affect the suspension and circulation of nanoparticles in the blood, accelerating the blood clearance of nanoparticles. In the present invention, we aim to vary and control the size, surface composition, and zeta potential of PEGylated MSNs to improve their BBB penetration ability. Their modification, spatial arrangement, and charge reveal the characteristics of MSNs, including minimal nonspecific binding and adequate circulation time in physiological environments, allowing them to be transported from the blood to the brain.

[0059] Inhibition of cancer metastasis

[0060] Cancer metastasis increases the mortality rate of patients suffering from cancer. Surprisingly, the inventors have discovered that MSNs, which are usually only used to deliver active ingredients, can have the effect of inhibiting cancer metastasis in in vitro or in vivo tests using animal models. However, non-mesoporous solid silica nanoparticles (SSNs) cannot have such an effect. Without being bound by theory, MSM itself would not inhibit tumor growth in situ, although the porous structure of MSNs may contribute to the effect of inhibiting cancer metastasis.

[0061] Thus, there is provided a method of inhibiting cell metastasis in a subject, comprising administering mesoporous silica nanoparticles (MSNs) to the subject. In one embodiment, the MSNs have a PEG surface modification to enhance bioavailability. In one embodiment, the MSNs have both PEG and TA surface modifications. In one embodiment, the MSNs have a particle size of 50 nm or less, preferably 30 nm or less. In one embodiment, the mesoporous silica nanoparticles are 1000 μm or less. 2 / g or less, preferably 500m 2 / g or less BET surface area. In one embodiment, the cell metastasis is cancer cell metastasis, such as lung cancer, breast cancer, colorectal cancer, melanoma, renal cancer, etc. In one embodiment, the administration route is systemic or local administration. In one embodiment, MSNs can be used with other chemotherapeutic drugs or biological drugs for combination therapy.

[0062] MSN Precoat

[0063] The use of protein corona to pre-coat nanoparticles is an alternative method to guide the biodistribution of nanoparticles or to avoid unwanted accumulation in non-target organs. The biological functions of all common proteins related to the fate of MSNs in vivo are identified. One approach is to pre-coat MSNs with pre-treated plasma, which lacks certain proteins that are believed to contribute to the accelerated blood clearance of nanoparticles. Another approach is to pre-coat MSNs with specific proteins found in the corona that have targeting capabilities or that can facilitate the nanoparticles to cross the BBB.

[0064] Potential diseases that can be treated based on the EPR effect and / or BBB penetration effect include, but are not limited to, brain-related cancers and CNS-related cancers. Specific diseases include, but are not limited to, acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, brainstem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumors, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), other brain-related conditions (cyst, neurofibromatosis, pseudotumor cerebri, tuberous sclerosis), schwannoma, juvenile pilocytic astrocytoma (JPA), pineal tumor, and rhabdoid tumor.

[0065] Examples of CNS-related diseases include, but are not limited to, addiction, arachnoid cysts, attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder, catalepsy, depression, encephalitis, epilepsy / seizures, infections, locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, Tourette's syndrome, Bell's palsy, cerebral palsy, epilepsy, motor neuron disease (MND), multiple sclerosis (MS), neurofibromatosis, sciatica, shingles, and stroke.

[0066] An in vitro BBB model is used for nanoparticle transport assays, which co-cultures brain capillary endothelial cells, brain pericytes, and astrocytes to simulate in vivo BBB function, and fluorescently labeled MSNs are used to directly observe particle accumulation in mouse cerebral blood vessels and brain tissues by two-photon fluorescence microscopy.

[0067] The following examples are provided to enable those skilled in the art to which the present invention pertains to better understand the present invention, and are not intended to limit the scope of the present invention. Working Example

[0068] Materials, Procedures, and Test Models

[0069] Preparation of RITC-conjugated APTMS

[0070] RITC was conjugated to APTMS by the reaction of the isothiocyanate group in RITC with the amino group in APTMS. The RITC-conjugated APTMS used herein was prepared by adding 8 mg of RITC in 5 mL of ethanol and introducing 10 μL of APTMS into the ethanol-RITC solution. The mixture was stirred in the dark for at least 3 hours to obtain the RITC-conjugated APTMS before use.

[0071] Transmission electron microscope (TEM)

[0072] To directly investigate and verify the appearance of silica nanoparticles, transmission electron microscopy (TEM) is used. TEM images were taken with a Hitachi H-7100 transmission electron microscope operating at an accelerating voltage of 100 kV. Samples dispersed in ethanol were dropped onto a carbon-coated copper grid and dried in air for TEM observation.

[0073] Dynamic Light Scattering (DLS) and Zeta Potential

[0074] Size measurements of silica nanoparticles in different solution environments were performed using dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS (Malvern, UK). The size of the (solvated) particles formed in different solutions (water and PBS buffer at pH 7.4) at room temperature was analyzed. The surface charge (zeta potential) of silica nanoparticles in aqueous solutions of different pH values ​​was measured by a Malvern Zetasizer Nano ZS coupled with an MPT-2 instrument, where the sample solutions were titrated from pH 6 to pH 8 and the data for different pH points were recorded.

[0075] elemental analysis

[0076] The mass percentages of carbon, nitrogen, oxygen, and hydrogen in the silica nanoparticles were determined by an elemental analyzer (Elementar Vario EL cube NCSH, Germany).

[0077] In vivo imaging system (IVIS) for detecting EPR effect and biodistribution of nanoparticles

[0078] In vivo biodistribution images of nanoparticles were obtained by IVIS imaging system (Lumina). BALB / c mice (4 weeks old) were purchased from Biolasco. For ectopic implantation, tumor-bearing mice were generated by subcutaneous injection of 4T1 (ATCC® CRL-2539TM) tumor cells. 4T1 cells were allowed to grow for 2-3 weeks and then intravenously injected into samples in PBS. 24 hours after injection, major organs (heart, lung, spleen, liver, and kidney), tumor, urine, and blood were carefully collected, and the fluorescence images and intensity of the collected samples were obtained by IVIS imaging system.

[0079] In vitro model of the blood-brain barrier (BBB)

[0080] The in vitro BBB model, purchased from Pharmacocell Co., Ltd. (Nagasaki, Japan), was constructed by triple cell co-culture using 12-well culture dishes containing transwell inserts seeded with plated brain endothelial cells, pericytes, and astrocytes. Prior to the experiment, the BBB culture dishes were incubated at 37°C under 5% carbon dioxide for 4 days to enhance tight junctions between cells. Charge-modified MSN-PEG nanoparticles were suspended in 0.3 mL of assay medium (0.33 mg / mL) and then added to the apical side of the BBB layer, and the model was cultured for 6 and 24 hours. In addition, sodium fluorescein (molecular weight 376; NaFluo) was used as a nonspecific transport marker. After the culture, the basolateral medium was collected and the Si concentration was detected by ICP-MS (inductively coupled plasma mass spectrometry).

[0081] Two-photon fluorescence microscopy for detecting nanoparticles in cerebral vasculature

[0082] Healthy ICR mice (27–30 g) were intravenously injected with 200 mg / kg of charge-modified MSN-PEG nanoparticles, and dynamic imaging of the mouse earlobe was performed by a multiphoton microscope (Olympus FVMPE-RS) with adjustable excitation frequency (800–1000 nm). After the nanoparticles ceased to circulate in the cerebral blood vessels, the mice were anesthetized and a craniotomy was performed. In this study, saline was used instead of placing a cover glass on the surface of the brain for short-term observation. To image the cerebral vasculature, 0.6 mL of 2.5% (w / v) fluorescein isothiocyanate dextran (FITC dextran, molecular weight 70 kDa) dissolved in sterile saline was intravenously injected into the mice. Depth profile images of charge-modified MSN-PEG nanoparticles in the mouse cerebrum were collected from 0–300 μm (axial interval was 1 μm) below the brain surface.

[0083] Quantification of pharmacokinetics and dox accumulation

[0084] Healthy BALB / c mice were given a single intravenous injection of 7.5 mg / kg Dox or Dox@NTT0_18. Blood samples were collected at 15, 30, 60, 180, 360, and 1440 min after injection to determine Dox concentrations in plasma and brain, respectively. After sampling, animals were killed and brains were harvested by perfusion with PBS. Dox was extracted from the samples (plasma and brain, respectively) for spectrophotometric determination of Dox concentrations.

[0085] U87 glioma animal model

[0086] U87-LUC glioma cells were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin (Invitrogen) at 37°C in a humidified 5% carbon dioxide atmosphere. Cells were harvested by trypsinization, washed once with phosphate-buffered saline (PBS), and resuspended (1 × 10 cells) in MEM for subsequent transplantation into the striatum of mouse brains. 5 The mice were anesthetized with 2% isoflurane gas and fixed on a stereotaxic frame for U87-LUC tumor cell implantation. A sagittal incision was made in the skin over the calvaria, and a hole was created in the exposed skull, 1.5 mm anterior and 2 mm lateral to the bregma, using a 23G needle. Five microliters of U87-LUC glioma cell suspension was injected 2 mm deep from the brain surface. The injection was performed for 3 min, after which the needle was withdrawn over 2 min. Brain tumor growth was monitored by IVIS and MRI.

[0087] Example 1

[0088] Preparation of mesoporous silica nanoparticles with various PEG ratios for functional group modification of nanoparticle surface

[0089] Mesoporous silica nanoparticles (MSNs) have a well-defined structure and a high density of surface silanol groups that can be modified by various organic functional groups. MSNs of different sizes were prepared in a highly diluted state, i.e., with a low concentration of surfactant, using ammonia as a base catalyst. The particle size was controlled by adjusting the ammonia concentration, the amount of TEOS added, and the reaction temperature. TA silane (N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride) was used as an exemplary charge modifier to provide positively charged groups on the surface of MSNs. As an example, 0.29 g of CTAB was dissolved in 150 mL of ammonium hydroxide solution (0.1-0.2 M) at the desired temperature (50-60 °C) in a sealed beaker. After 15 min of stirring, the sealing membrane was removed and the solution was stirred vigorously (600 rpm) while RITC-conjugated APTMS in 2.5 mL of ethanol and TEOS (0.8–0.9 M) in 2–2.5 mL of ethanol were added. After 1 h of stirring, 550 μL of PEG silane (2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane) with different molar ratios of PEG silane to TA silane were reacted in 2 mL of ethanol (PEG / TA ratios were 15:1, 10:1, 7:1, 3:1, 2:1, and 1:2, and the amount of TA silane ranged from 0.04 to 1.2 mL). The mixture was stirred for 30 min, after which the mixture was aged at the desired temperature (50–60 °C) without stirring for at least 12 h. The solution was then sealed and subjected to hydrothermal treatment in a 70 °C oven for 24 h. The as-synthesized samples were washed and collected by centrifugation or a cross-flow system. To remove the surfactant in the pores of MSNs, the as-synthesized samples were incubated in 40 mL of acidic ethanol containing 678 μL and 40 μL of hydrochloric acid (37%) for the first and second times at 60 °C, respectively, with an extraction time of 1 h. The products were washed, collected by centrifugation or a cross-flow system, and finally stored in 90% ethanol. To synthesize MSN-PEGs modified with different functional groups, the TA silane was replaced with PEI silane, EDPTMSN silane, or other functional silanes.

[0090] Example 2

[0091] TEM and DLS measurements

[0092] The MSNs synthesized in Example 1 were subjected to TEM measurement, and the results are shown in Figure 1. The particle sizes and their standard deviations are shown in Table 1. The TEM results show that the 30 nm MSNs with various modifications have an average particle size of about 25-35 nm, and the 50 nm MSNs with various modifications have an average particle size of about 40-60 nm, with both particle size standard deviations being small, which suggests that they reflect the uniformity of the particles. [Table 1]

[0093] The particle sizes of MSNs with various modifications measured by dynamic light scattering (DLS) in different resolution environments are shown in Table 2. The DLS results show that all MSNs are well dispersed in the buffer solution within the range of about 35 nm–45 nm or 50–70 nm. [Table 2]

[0094] elemental analysis

[0095] During the synthesis of MSN-PEG+TA, different molar ratios of PEG silane and TA silane were used in the reaction to modulate the PEG / TA ratio in MSNs. To quantify the functional groups in MSN-PEG+TA nanoparticles, the elemental composition of MSN-PEG+TA nanoparticles was measured by elemental analyzer. The molar ratio of PEG groups to TA groups in MSN-PEG+TA (PEG / TA) is derived from the mass percentage of nitrogen and carbon in MSN-PEG+TA particles. The PEG / TA ratios of MSN-PEG+TA (1:2), (2:1), and (10:1) derived from elemental analysis are approximately 0.64, 2.67, and 6.13.

[0096] Example 3

[0097] Influence of surface charge and spatial arrangement of functional groups on biodistribution and tumor targeting ability

[0098] It has been demonstrated that MSNs exhibit excellent tumor targeting capabilities based on the EPR effect, with several important determinants to be considered: (1) the particle size should be less than 100 nm, preferably in the range of about 20 nm to 50 nm, e.g., about 30 nm; (2) the outer surface should be covered with PEG, and the modifications should be hidden within the PEG layer. (3) The surface charge and the ratio of PEG / charge-modifying moiety should be limited within a certain range. To evaluate the influence of the spatial arrangement of functional groups on the EPR effect, MSNs with similar size and zeta potential but different lengths or molecular weights of positively charged molecules were synthesized. The PEG for PEGylating MSNs has a molecular weight of 459-591, and the positively charged groups for surface modification are trimethoxysilylpropyl-modified polyethyleneimine (PEI silane, molecular weight 1500-1800), N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (TA silane, molecular weight 258), or N-[3-(trimethoxysilyl)propyl]ethylenediamine (EDPTMS, molecular weight 222). The PEI silane, which has a larger molecular weight, is expected to be exposed to the outside beyond the PEG layer, while the TA and EDP silanes have a smaller molecular weight than the PEG silane, and therefore the chain length is shorter, and the quaternary amine of TA and the primary and secondary amines of EDP are expected to be hidden within the PEG layer. The synthetic diameter (TEM), hydrodynamic diameter (DLS) in water and buffer, and zeta potential of MSN-PEG+PEI, MSN-PEG+TA, and MSN-PEG+EDP are almost identical (Table 3). The EPR effect of these particles is examined by injecting the particles through the tail vein of tumor-bearing mice. One day after injection, the accumulation of the particles in the tumor and organs was determined by IVIS. MSN-PEG+TA and MSN-PEG+EDP showed strong fluorescent signals in the tumor, and the ratio of the tumor signal to the liver signal was greater than 3. This means that the particles accumulate in the tumor and have excellent EPR effect. However, MSN-PEG+PEI, although it has similar size and zeta potential as MSN-PEG+TA, does not accumulate in tumors (Table 3). To modulate the EPR effect, not only the functional groups are hidden in the PEG layer, but also the surface charge of MSNs is important. It is well known that PEGylation improves blood circulation and accumulation in tumors, but the improvement is not sufficient. The liver-to-tumor ratio (tumor / liver) where the particles accumulate is about 1.2 for 30 nm MSN-PEG and about 0.35 for 50 nm MSN-PEG (Figure 2).By varying the molar ratio of TA to PEG (PEG / TA) during the synthesis process to modulate the composition of surface functional groups and the zeta potential, the EPR effect can be significantly enhanced. The particle accumulation ratio values ​​(tumor / liver) increased by 2–3, indicating a 2–8.6-fold improvement. The 30 nm MSN-PEG+TA nanoparticles modified with PEG / TA (PEG silane / TA silane) in the ratio of 15:1 to 2:1 (in the synthesis process) with an increased zeta potential (pH 7.4 state) from -15 to +7 mV show higher particle accumulation ratio values ​​(tumor / liver) than the MSN-PEG, MSN-TA (zeta potential +31), and PEG / TA (1:2) modified nanoparticles (zeta potential +21) (Figure 3). Similar results were obtained when the particle size of MSN-PEG+TA was 50 nm, the PEG / TA ratio was 7:1 to 2:1, and the zeta potential (pH 7.4 state) was increased from +12 to +18 mV, and the particles showed a higher tumor targeting ability than the 50 nm MSN-PEG. The results indicate that the surface charge and PEG / TA ratio of MSN-PEG+TA in a certain range enhance the tumor targeting ability of the nanoparticles. [Table 3]

[0099] Example 4

[0100] Effect of surface charge on BBB penetration ability

[0101] Since nanoparticles smaller than 100 nm are favorable for drug transport through the BBB, delivering therapeutic drugs to the brain remains a major challenge. In this study, the effects of size, composition, and zeta potential of PEGylated MSNs on BBB penetration were investigated in vitro and in vivo. Three different sizes (10, 30, and 50 nm) of MSNs with different surface modifications were synthesized, and particles with BBB penetration ability were quickly screened using a BBB kit, an in vitro BBB model made by primary culture of brain capillary endothelial cells, brain pericytes, and astrocytes in rats (Wistar rats). 30 nm PEGylated MSNs, whose surface was modified with positively charged TA molecules, showed relatively good penetration through the cell layer of the BBB in an in vitro assay. To understand the BBB penetration ability of nanoparticles in vivo, the distribution of nanoparticles in the blood vessels of mouse brain was monitored using two-photon fluorescence microscopy. Fluorescently labeled nanoparticles were administered via the tail vein. Two days after injection, we detected cerebral blood vessels located within a depth of 0-300 μm from the surface. Meanwhile, to map the vasculature and reveal the boundaries of the vascular wall, FITC-dextran was intravenously injected. When the fluorescent signal from the nanoparticles overlapped with the signal of FITC-dextran (green signal), a yellow or red signal appeared, meaning that the nanoparticles were not in the blood vessels but could pass the BBB and enter the brain tissue. The 3D image of the cerebral blood vessels shows a very large number of red signals from MSN-PEG+TA nanoparticles distributed in the cerebral blood vessel walls and brain tissue regions (Figure 4A). We further investigated the intracerebral distribution of MSN-PEG+TA by observing the dispersion pattern of the nanoparticles in brain tissue sections. At different locations in the brain tissue, the nanoparticles were detected.

[0102] The results showed that 30 nm MSN-PEG+TA modified with a certain range of PEG / TA ratios (10:1 to 2:1) had the potential to cross the BBB and enter brain tissue. However, nanoparticles modified with negatively charged THPMP molecules (MSN-PEG+THPMP) did not exhibit BBB penetration ability (Figure 4B). To show BBB penetration ability in vivo, nanoparticles must have minimal nonspecific binding and adequate circulation time in physiological environment. Furthermore, the physiochemical properties of nanoparticles determine the passage mechanism through the BBB. Thus far, we have described the mechanisms of nanoparticles passing through the BBB, including receptor- or absorptive-mediated transcytosis by endothelial cells and opening tight junctions between endothelial cells, but it is still difficult to develop nanoparticles with BBB penetration ability for biological applications. In the present invention, we demonstrate that by hiding functional groups (TA molecules) within the PEG layer and modulating the surface PEG / TA ratio (10:1 to 1:2, preferably about 10:1 to 2:1) to change the zeta potential (at pH 7.4) in the range of -13 to +21 mV (preferably about -13 to +7 mV), the nanoparticles can be made to penetrate the BBB for delivery of therapeutic agents for CNS diseases and brain tumors to the brain.

[0103] Example 5

[0104] Pharmacokinetics of Dox and Dox@MSN-PEG+TA in plasma and brain

[0105] To preliminary quantify the extended blood circulation time and enhanced BBB penetration ability of MSN-PEG+TA, the pharmacokinetics of the chemotherapeutic drug doxorubicin (Dox) was analyzed with and without MSN-PEG+TA encapsulation. Mice were administered a single dose of Dox or Dox@NTT0_18 (MSN-PEG+TA-loaded Dox) by intravenous injection (all Dox doses were 7.5 mg / kg). To determine Dox concentrations in plasma and brain, blood samples were taken at 15, 30, 60, 180, 360, and 1440 min after injection, and animals were sacrificed and perfused with PBS at each time point. Dox was extracted from plasma and brain, and Dox concentrations were measured using a spectrophotometer. Concentration vs. time curves of Dox in plasma with and without encapsulated MSN-PEG+TA were also plotted. Plasma Dox concentrations were barely detectable (less than 0.2 μg / mL) 15 min after injection of Dox solution, but Dox was still present in mice injected with Dox@NTT0_18 after 6 h. Brain analysis in these perfused mice showed that administration of Dox@NTT0_18 resulted in 2-6.6-fold higher accumulation of Dox in the brain than administration of Dox solution. These results reveal that Dox encapsulated in MSN-PEG+TA nanoparticles can prolong blood circulation time and enhance BBB permeability.

[0106] Example 6

[0107] Dox@MSN-PEG+TA for the treatment of brain tumors

[0108] The 30 nm MSN-PEG+TA particles have tumor targeting (EPR effect) and BBB permeation properties. This is the advantage of MSN-PEG+TA nanoparticles as drug delivery nanocarriers for the treatment of brain tumors. Dox is a well-known anticancer drug approved for the treatment of multiple cancers. In vitro, Dox shows anti-glioma cell activity, but could not cross the BBB and enter the brain. Also, Dox has not been approved for the treatment of brain cancer. Our MSN-PEG+TA nanoparticles provide the possibility to deliver Dox into the brain for the treatment of brain cancer. Dox@MSN-PEG+TA was synthesized by incubating Dox in MSN-PEG+TA solution for 1 h, washing twice with water to remove unencapsulated Dox, and collected by centrifugation. To evaluate the anti-brain tumor efficacy of Dox@MSN-PEG+TA in vivo, U87-LUC brain cells were orthotropically transplanted into nude mice to form the U87-LUC xenograft mouse model. U87-LUC cells could represent a luminescent enzyme for tumor cell quantification in vivo. Four days after tumor implantation, the same Dox dose (10 mg / kg) of free Dox and Dox@MSN-PEG+TA, and approximately 250 mg / kg of MSN-PEG+TA, were administered three times every four days via the tail vein of the U87-LUC xenograft mouse model, respectively, and the body weight and tumor size were measured during the study period. During the treatment period, the tumor size of Dox and Dox@MSN-PEG+TA decreased, but the high toxicity of Dox weakened the mice and led to the death of the host. In contrast, mice treated with Dox@MSN-PEG+TA showed a weight loss during the treatment period, but recovered when the administration was stopped. MRI images of the brains of mice in the Dox@MSN-PEG+TA treatment group showed significant tumor shrinkage on day 13, and by day 34, the tumor was almost undetectable as indicated by the empty space (not shown). The life span of mice treated with Dox@MSN-PEG+TA was significantly extended due to the disappearance of tumors. To evaluate the EPR effect and BBB permeability of MSN-PEG+TA and Dox@MSN-PEG+TA, mice were killed 24 hours after the last injection, and the brains were collected and fixed for preparing frozen sections. The distribution of MSN-PEG+TA and Dox@MSN-PEG+TA in brain tissue and tumor was evaluated from tumor sections of mice treated with nanoparticles. DAPI was used to stain the nuclei of cells, and tumor tissue was identified by the hyperplastic areas of cells stained with DAPI (shown in blue). Mice treated with MSN-PEG+TA showed a lot of accumulation of nanoparticles (shown in red) in the center and periphery of the tumor. This phenomenon may be due to the combination of EPR effect and BBB permeability of MSN-PEG+TA (not shown). Brain sections of mice treated with Dox@MSN-PEG+TA showed that the tumor area was much smaller than that of the PBS group, due to the anti-brain tumor effect of Dox@MSN-PEG+TA. MSN-PEG+TA and Dox@MSN-PEG+TA are clearly different. Dox@MSN-PEG+TA is not only accumulated in the tumor area, but also in non-tumor areas. The signal of Dox@MSN-PEG+TA can be detected in various regions throughout the brain (not shown). These results indicate that once leaky vasculature is formed during tumor growth, the EPR effect of Dox@MSN-PEG+TA dominates the biodistribution and delivers Dox to the tumor area, thus killing tumor cells and shrinking the tumor. Once the tumor shrinks and the EPR effect weakens, the BBB crossing phenomenon of Dox@MSN-PEG+TA nanoparticles is easily observed. In clinical cases, cancer cells around the tumor can infiltrate into normal brain tissue, which makes it difficult to deliver therapeutic drugs. Because the BBB and blood vessels in the normal area are intact, they block the therapeutic drugs. The BBB permeability of Dox@MSN-PEG+TA has the potential to deliver Dox into the intact area of ​​the BBB to kill invading cancer cells or to kill remaining cancer cells after tumor removal surgery. Therefore, MSN-PEG+TA, which has both the EPR effect and BBB permeation ability as a drug delivery system, is beneficial for the treatment of cancer, especially brain-related cancer, and CNS diseases.

[0109] The materials, reactions, conditions, and parameters in the examples are for illustrative purposes only and are not intended to limit the materials or preparation methods.

[0110] Examples of brain-related and CNS-related cancers include, but are not limited to, acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, brain stem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumors, oligodendroglioma, pituitary tumor, primitive neuroectodermal tumor (PNET), other brain-related conditions (cysts, neurofibromatosis, pseudotumor cerebri, tuberous sclerosis), schwannoma, juvenile pilocytic astrocytoma (JPA), pineal tumor, and rhabdoid tumor.

[0111] Examples of CNS-related diseases include, but are not limited to, addiction, arachnoid cysts, attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder, catalepsy, depression, encephalitis, epilepsy / seizures, infections, locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, Tourette's syndrome, Bell's palsy, cerebral palsy, epilepsy, motor neuron disease (MND), multiple sclerosis (MS), neurofibromatosis, sciatica, shingles, and stroke.

[0112] Example 7

[0113] In vitro testing to inhibit cancer cell metastasis

[0114] To evaluate the possibility of inhibiting cancer metastasis by MSN treatment, a wound-healing assay was employed. MSN particles with different surface modifications or particle sizes are used in the assay. Solid silica nanoparticles (SSNs), i.e., nanoparticles with virtually no pores, are also used in the assay as a comparison example. The wound-healing assay is carried out in the following steps: Two wells of Culture-Inserts from Ibidi are transferred to a 24-well plate and 4T1 cells (2 × 10 4Cells / well) were seeded into the two compartments of Culture-Inserts and incubated for 24 hours. After incubation, the inserts were removed to create a uniform wound. The wells were washed twice with PBS to remove detached cells, and cultured in RPMI medium with 1% fetal bovine serum and 200 μg / mL MSNs or SSNs. Images were taken under a microscope after 0, 16, and 24 hours, and the wound healing rate was counted by ImageJ. The detailed parameters are shown in Table 4.

[0115] [Table 4]

[0116] Figure 5A shows a comparison of the wound healing rates of each sample after 16 and 24 hours. The results showed that MSNs with various surface modifications and sizes showed an inhibitory effect on cell migration, whereas SSNs did not.

[0117] Boyden chamber assay was also employed to evaluate the potential of MSN treatment to inhibit cancer metastasis. To evaluate the ability of MSNs to inhibit cell migration, cells were treated with 200 μg / mL of MSNs or SSNs for 24 h, followed by 2 × 10 5 4T1 cells / well were seeded in a 6-well plate and incubated for 24 h. Afterwards, the cells were harvested and cultured in a Boyden chamber (7 × 10 4The cells were transferred to the upper side of the membrane (cells / well). A hollow plastic chamber was used for the Boyden chamber assay, one end of which was sealed with a porous membrane, the chamber was placed on the well, and RPMI medium was added. The cells were placed on the upper side of the chamber and allowed to migrate to the other side of the membrane through the pores. After 24 hours, the cells were fixed with 4% formaldehyde solution and stained with 0.5% crystal violet. The non-migrated cells on the upper side of the chamber were removed with a cotton swab, and images of the migrated cells were taken under a microscope. Figure 5B shows a comparison of the percentage of cell coverage (migrated cells) on the lower layer of each sample. The results showed that MSNs with various surface modifications, including PEG modification and PEG modification combined with TA modification as described above, and various sizes, showed the effect of inhibiting cell migration, but no such effect was observed for SSNs. Such results may be evidence that the mesoporosity of silica nanoparticles may contribute to the effect of inhibiting cell migration.

[0118] Example 8

[0119] In vivo testing in mice

[0120] In vivo studies were performed on mice to evaluate the therapeutic effects of MSNs. 6 BALB / c mice with luciferase-4T1 cancer cells (luciferase-labeled breast cancer cells) implanted on the back were used as an in vivo test model. In this spontaneous cancer metastasis model, cancer cells spread from the implantation site to secondary sites (metastatic sites: lungs, lymph nodes, etc.) as soon as the implanted tumor grew. On days 12, 15, and 18, 25 nm MSN-PEG+TA was injected intravenously (200 mg / kg) or intratumorally (20 mg / kg) into the mice. To track cancer metastasis, luminescence images were taken by an IVIS system on days 21, 28, 32, and 35. On day 35, the lungs of the mice were removed and stained with India ink. After a few minutes, tumor tissue appears as white nodules in the black lungs. The metastasis level can be determined by counting the tumors. The weight and tumor volume of the mice were measured twice a week.

[0121] Figure 6A shows that the body weight of mice measured in each group remained almost constant, which means that MSN-PEG+TA may not be toxic to mice. Meanwhile, the tumor volumes measured on different days indicated that MSN-PEG+TA may not be able to inhibit tumor growth in situ.

[0122] Figure 7 shows the results of the cancer metastasis level to the lungs, indicating that both intravenous injection and intratumoral administration of MSN-PEG+TA inhibited metastasis.

[0123] FIG. 8 is a luminescence image showing that the levels of metastasis from the back of mice that received 25 nm of MSN-PEG+TA intravenously or intratumorally to other parts of the body (lungs and lymph nodes) were lower than those of control mice.

[0124] Those skilled in the art should understand that various changes and modifications may be made to the teachings and disclosure of the present invention without departing from the spirit and scope of the present application. Based on the above, it is intended that such changes and modifications are within the scope of the present application, provided that they fall within the scope defined in the appended claims and their equivalents.

Claims

1. A surface-organically modified mesoporous silica nanoparticle, a zeta potential in the range of −22 mV to +25 mV at pH 7.4 and a particle size of 20 nm to 50 nm as measured by transmission electron microscopy (TEM); the organic modification comprises a poly(ethylene glycol) (PEG) moiety and any one of: (1) a positively charged group-containing molecule, (2) a positively charged group-containing oligomer, and (3) a positively charged group-containing polymer; the (1) positively charged group-containing molecule, the (2) positively charged group-containing oligomer, and the (3) positively charged group-containing polymer are hidden within the layer of PEG; the molar ratio of the PEG moiety to the (1) positively charged group-containing molecule, the (2) positively charged group-containing oligomer, and the (3) positively charged group-containing polymer is in the range of 15:1 to 2:1; Mesoporous silica nanoparticles.

2. Mesoporous silica nanoparticles as described in claim 1, having a particle size of 20 nm to 30 nm as measured by TEM.

3. 2. The mesoporous silica nanoparticles according to claim 1, having a zeta potential at pH 7.4 in the range of -15 mV to +7 mV.

4. 2. The mesoporous silica nanoparticles according to claim 1, wherein said organic modification is conducted by a material selected from poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), and PEG-PPG copolymers.

5. The mesoporous silica nanoparticles according to claim 1, wherein any one of the (1) positively charged group-containing molecule, the (2) positively charged group-containing oligomer and the (3) positively charged group-containing polymer is selected from polyethyleneimine (PEI); N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride (TA), N-[3-(trimethoxysilyl)propyl]ethylenediamine (EDPT), N1-(3-trimethoxysilylpropyl)diethylenetriamine; 3-aminopropyltrimethoxysilane (APTMS) and 3-aminopropyltriethoxysilane.

6. The surface of the nanoparticles may be modified with additional alkoxysilane terminated (poly)alkylene(poly)amines; propyltriethoxysilane, butyltrimethoxysilane, octyltrimethoxysilane, diphenyldiethoxysilane, n-octyltriethoxysilane, mercaptopropyltrimethoxysilane, chloromethyltrimethoxysilane, isobutyltriethoxysilane, ethyltrimethoxystyrenesilane, methyltriethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane, and further comprising a modification derived from at least one surface modifier selected from additional organoalkoxysilanes such as N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (EDTAS), (3-trihydroxysilyl)propylmethylphosphonic acid (THPMP), methyltriacetoxysilane (MTAS), (3-mercatopropyl)trimethoxysilane (MPTMS), zwitterionic silanes, and the like. The mesoporous silica nanoparticles according to claim 5 .

7. 2. The mesoporous silica nanoparticles according to claim 1, wherein a molar ratio of the PEG moiety to any one of the (1) positively charged group-containing molecule, the (2) positively charged group-containing oligomer and the (3) positively charged group-containing polymer is in the range of 10:1 to 3:

1.

8. The mesoporous silica nanoparticles of claim 1 , further comprising a bioactive component disposed thereon and / or loaded thereon.

9. The mesoporous silica nanoparticles according to claim 8, wherein the bioactive component is selected from small molecule drugs, proteins such as enzymes and protein drugs, antibodies, vaccines, antibiotics, or nucleotide drugs.

10. A method for preparing mesoporous silica nanoparticles (MSNs) having a surface modification according to any one of claims 1 to 9, comprising the steps of: (a) providing an alkaline solution containing a surfactant at a concentration sufficient to form micelles; (b) introducing a silane source into the alkaline solution; (c) introducing a surface modifier comprising at least one PEG-modified silane and at least one positively charged group-containing silane into the alkaline solution, wherein the molar ratio of the PEG-modified silane to the positively charged group-containing silane is in the range of 15:1 to 2:1; (d) subjecting the alkaline solution to a hydrothermal treatment; (e) collecting the product; (f) removing residual surfactant from the product; Optionally, (g) purifying or washing the product; The method includes:

11. The method of claim 10 , wherein the surfactant comprises a cationic surfactant, an anionic surfactant, a nonionic surfactant, or a combination thereof.

12. 11. The method of claim 10, wherein the silane source comprises tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), sodium silicate, or a mixture thereof.

13. The method of claim 10, wherein the PEG-modified silane is 2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane (PEG-trimethoxysilane) and the positively charged group-containing silane is selected from trimethoxysilylpropyl (polyethyleneimine), N-[3-(trimethoxysilyl)propyl]-N,N,N-trimethylammonium chloride, N-[3-(trimethoxysilyl)propyl]ethylenediamine, 3-aminopropyltrimethoxysilane (APTMS) and 3-aminopropyltriethoxysilane.

14. 11. The method of claim 10, wherein the surface modifier further comprises at least one agent selected from propyltriethoxysilane, butyltrimethoxysilane, octyltrimethoxysilane, diphenyldiethoxysilane, n-octyltriethoxysilane, mercaptopropyltrimethoxysilane, chloromethyltrimethoxysilane, isobutyltriethoxysilane, ethyltrimethoxystyrenesilane, methyltriethoxysilane, phenyltriethoxysilane (PTEOS), phenyltrimethoxysilane (PTMOS), methyltrimethoxysilane (MTMOS), ethyltriacetoxysilane (ETAS), N-(trimethoxysilylpropyl)ethylenediaminetriacetic acid (EDTAS), (3-trihydroxysilyl)propylmethylphosphonic acid (THPMP), methyltriacetoxysilane (MTAS), (3-mercatopropyl)trimethoxysilane (MPTMS), and zwitterionic silanes.

15. 11. The method of claim 10, wherein the silane source is a mixture of TEOS and APTMS, a mixture of THPMP, APTMS and TEOS, a mixture of EDTAS, APTMS and TEOS, a mixture of PTEOS and TEOS, or a mixture of PTMOS and TEOS.

16. An inhibitor of cell metastasis in a subject, comprising the mesoporous silica nanoparticles described in any one of claims 1 to 9, which is administered systemically or locally to the subject.

17. The mesoporous silica nanoparticles are 1000m 2 The cell metastasis inhibitor of claim 16, wherein the subject has a BET surface area of ​​0.1 μg or less.

18. The cell metastasis inhibitor for a subject according to claim 16, wherein the mesoporous silica nanoparticles have a BET surface area of ​​500 m 2 / g or less.

19. The method for inhibiting cell metastasis in a subject according to claim 16 , wherein the cell metastasis is cancer cell metastasis.

20. A cell metastasis inhibitor for a subject described in claim 16, wherein the cell metastasis is breast cancer cell metastasis.

Citation Information

Patent Citations

  • Silica-based biomolecule carrier, pharmaceutical composition containing same, method for producing same, and use thereof

    JP2018533543A